ITFG2

Summary

ITFG2 (integrin alpha FG-GAP repeat containing 2, HGNC:30879) is a protein-coding gene on chromosome 12p13.33, encoding KICSTOR complex protein ITFG2 (Q969R8). As part of the KICSTOR complex functions in the amino acid-sensing branch of the TORC1 signaling pathway.

Involved in cellular response to amino acid starvation; cellular response to glucose starvation; and negative regulation of TORC1 signaling. Located in Golgi apparatus and lysosomal membrane. Part of KICSTOR complex.

Source: NCBI Gene 55846 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC)
• Clinical variants (ClinVar): 161 total — 1 likely-pathogenic
• MANE Select transcript: NM_018463

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30879
Approved symbol	ITFG2
Name	integrin alpha FG-GAP repeat containing 2
Location	12p13.33
Locus type	gene with protein product
Status	Approved
Aliases	MDS028, KICS3
Ensembl gene	ENSG00000111203
Ensembl biotype	protein_coding
OMIM	617421
Entrez	55846

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 11 protein_coding, 7 protein_coding_CDS_not_defined, 6 nonsense_mediated_decay, 3 retained_intron

ENST00000228799, ENST00000534935, ENST00000535564, ENST00000537183, ENST00000537710, ENST00000537851, ENST00000538822, ENST00000540300, ENST00000540662, ENST00000540929, ENST00000541659, ENST00000543029, ENST00000545509, ENST00000552005, ENST00000643039, ENST00000644123, ENST00000644517, ENST00000645513, ENST00000905243, ENST00000905244, ENST00000905245, ENST00000905246, ENST00000905247, ENST00000917240, ENST00000917241, ENST00000917242, ENST00000944946

RefSeq mRNA: 1 — MANE Select: NM_018463 NM_018463

CCDS: CCDS8513

Canonical transcript exons

ENST00000228799 — 12 exons

Exon	Start	End
ENSE00000713129	2818106	2818277
ENSE00001882716	2824090	2825076
ENSE00003462568	2821543	2821596
ENSE00003507139	2820086	2820225
ENSE00003518718	2822794	2822911
ENSE00003525213	2821262	2821359
ENSE00003530883	2817909	2817950
ENSE00003536425	2820724	2820872
ENSE00003629225	2817223	2817318
ENSE00003635081	2821692	2821792
ENSE00003663351	2823770	2823943
ENSE00003844924	2812668	2812856

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 95.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.1812 / max 129.1825, expressed in 1799 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
123451	15.1812	1799

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of thyroid gland	UBERON:0001119	95.38	gold quality
left lobe of thyroid gland	UBERON:0001120	94.80	gold quality
granulocyte	CL:0000094	94.57	gold quality
body of pancreas	UBERON:0001150	94.37	gold quality
sural nerve	UBERON:0015488	94.24	gold quality
thyroid gland	UBERON:0002046	94.08	gold quality
right uterine tube	UBERON:0001302	93.81	gold quality
left ovary	UBERON:0002119	92.49	gold quality
right ovary	UBERON:0002118	92.42	gold quality
metanephros cortex	UBERON:0010533	92.30	gold quality
adenohypophysis	UBERON:0002196	92.08	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.03	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.96	gold quality
mucosa of transverse colon	UBERON:0004991	91.90	gold quality
spleen	UBERON:0002106	91.89	gold quality
endocervix	UBERON:0000458	91.86	gold quality
cerebellar hemisphere	UBERON:0002245	91.86	gold quality
right lobe of liver	UBERON:0001114	91.82	gold quality
minor salivary gland	UBERON:0001830	91.75	gold quality
cerebellar cortex	UBERON:0002129	91.75	gold quality
body of stomach	UBERON:0001161	91.46	gold quality
body of uterus	UBERON:0009853	91.42	gold quality
right adrenal gland cortex	UBERON:0035827	91.28	gold quality
right adrenal gland	UBERON:0001233	91.22	gold quality
pituitary gland	UBERON:0000007	91.19	gold quality
tibial nerve	UBERON:0001323	91.19	gold quality
ventricular zone	UBERON:0003053	91.09	gold quality
apex of heart	UBERON:0002098	91.07	gold quality
transverse colon	UBERON:0001157	91.05	gold quality
saliva-secreting gland	UBERON:0001044	90.96	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.97
E-MTAB-6379	no	201.62
E-CURD-112	no	2.70

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting ITFG2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-5571-5P	99.49	66.99	1764
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-363-5P	99.46	64.51	1015
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-4725-5P	98.67	65.42	628
HSA-MIR-504-5P	98.67	65.40	631
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-4720-3P	98.50	68.88	988
HSA-MIR-4662B	98.33	66.37	1163
HSA-MIR-4647	98.30	66.41	1139
HSA-MIR-4483	98.09	64.12	1642
HSA-MIR-432-5P	98.00	68.13	989

Literature-anchored findings (GeneRIF, showing 1)

• identification of a protein complex (KICSTOR) that is composed of four proteins, KPTN, ITFG2, C12orf66 and SZT2, and that is required for amino acid or glucose deprivation to inhibit mTORC1 in cultured human cells (PMID:28199306)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	itfg2	ENSDARG00000002174
mus_musculus	Itfg2	ENSMUSG00000001518
rattus_norvegicus	Itfg2	ENSRNOG00000006264

Protein

Protein identifiers

KICSTOR complex protein ITFG2 — Q969R8 (reviewed: Q969R8)

Alternative names: Integrin-alpha FG-GAP repeat-containing protein 2

All UniProt accessions (7): A0A0S2Z5P1, A0A2R8Y7E0, Q969R8, F5H1D0, H0YFM4, H0YG72, H0YGR0

UniProt curated annotations — full annotation on UniProt →

Function. As part of the KICSTOR complex functions in the amino acid-sensing branch of the TORC1 signaling pathway. Recruits, in an amino acid-independent manner, the GATOR1 complex to the lysosomal membranes and allows its interaction with GATOR2 and the RAG GTPases. Functions upstream of the RAG GTPases and is required to negatively regulate mTORC1 signaling in absence of amino acids. In absence of the KICSTOR complex mTORC1 is constitutively localized to the lysosome and activated. The KICSTOR complex is also probably involved in the regulation of mTORC1 by glucose.

Subunit / interactions. Part of the KICSTOR complex composed of KPTN, ITFG2, KICS2 and SZT2. SZT2 probably serves as a link between the other three proteins in the KICSTOR complex and may mediate the direct interaction with the GATOR complex via GATOR1. The KICSTOR complex interacts directly with the GATOR1 complex and most probably indirectly with the GATOR2 complex in an amino acid-independent manner.

Subcellular location. Lysosome membrane.

Isoforms (2)

UniProt ID	Names	Canonical?
Q969R8-1	1	yes
Q969R8-2	2

RefSeq proteins (1): NP_060933* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028994	Integrin_alpha_N	Homologous_superfamily
IPR031793	KICSTOR_ITFG2	Family
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

Pfam: PF15907

UniProt features (8 total): repeat 2, modified residue 2, splice variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
9VAN	ELECTRON MICROSCOPY	2.9
9V80	ELECTRON MICROSCOPY	2.95
9V86	ELECTRON MICROSCOPY	3.04
9V9N	ELECTRON MICROSCOPY	3.08
9V6E	ELECTRON MICROSCOPY	3.19
9O5A	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969R8-F1	87.05	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 104, 220

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9639288	Amino acids regulate mTORC1
R-HSA-2262752	Cellular responses to stress
R-HSA-8953897	Cellular responses to stimuli
R-HSA-9711097	Cellular response to starvation

MSigDB gene sets: 164 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, GOBP_B_CELL_ACTIVATION, GOCC_VACUOLAR_MEMBRANE, CREBP1_Q2, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, CREB_Q4, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_TOR_SIGNALING, E4F1_Q6, CREB_Q2_01, GOBP_CELLULAR_RESPONSE_TO_STARVATION, GOBP_IMMUNE_EFFECTOR_PROCESS, GOBP_TOR_SIGNALING, GOBP_MATURE_B_CELL_DIFFERENTIATION, GOBP_CELLULAR_RESPONSE_TO_GLUCOSE_STARVATION

GO Biological Process (6): germinal center B cell differentiation (GO:0002314), regulation of TOR signaling (GO:0032006), cellular response to amino acid starvation (GO:0034198), cellular response to glucose starvation (GO:0042149), negative regulation of TORC1 signaling (GO:1904262), integrin-mediated signaling pathway (GO:0007229)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): nucleoplasm (GO:0005654), lysosomal membrane (GO:0005765), Golgi apparatus (GO:0005794), cytosol (GO:0005829), KICSTOR complex (GO:0140007), lysosome (GO:0005764), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cellular response to starvation	1
Cellular responses to stimuli	1
Cellular responses to stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cellular response to starvation	2
cytoplasm	2
mature B cell differentiation involved in immune response	1
TOR signaling	1
regulation of intracellular signal transduction	1
response to amino acid starvation	1
negative regulation of TOR signaling	1
TORC1 signaling	1
regulation of TORC1 signaling	1
cell surface receptor signaling pathway	1
binding	1
nuclear lumen	1
lysosome	1
lytic vacuole membrane	1
endomembrane system	1
intracellular membrane-bounded organelle	1
protein-containing complex	1
lytic vacuole	1

Protein interactions and networks

STRING

1108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ITFG2	KICS2	Q96MD2	997
ITFG2	KPTN	Q9Y664	997
ITFG2	SZT2	Q5T011	996
ITFG2	SAMTOR	Q1RMZ1	892
ITFG2	DEPDC5	O75140	818
ITFG2	NPRL2	Q8WTW4	709
ITFG2	NPRL3	Q12980	686
ITFG2	WDR24	Q96S15	684
ITFG2	WDR59	Q6PJI9	672
ITFG2	MIOS	Q9NXC5	649
ITFG2	SEH1L	Q96EE3	634
ITFG2	TBC1D7	Q9P0N9	588
ITFG2	CASTOR1	Q8WTX7	547
ITFG2	SLC38A9	Q8NBW4	543
ITFG2	SEC13	P55735	519

IntAct

34 interactions, top by confidence:

A	B	Type	Score
VWCE	HSPA5	psi-mi:“MI:0914”(association)	0.640
OTUD3	ITFG2	psi-mi:“MI:0915”(physical association)	0.560
ITFG2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
BTN2A1	POTEF	psi-mi:“MI:0914”(association)	0.530
INPP5A	RCCD1	psi-mi:“MI:0914”(association)	0.530
VWCE	ZNF316	psi-mi:“MI:0914”(association)	0.530
KPTN	EIF4G3	psi-mi:“MI:0914”(association)	0.530
HSPB9	USP12	psi-mi:“MI:0914”(association)	0.530
SAMTOR	PER1	psi-mi:“MI:0914”(association)	0.530
ITFG2	DEPDC5	psi-mi:“MI:0914”(association)	0.530
PROSER2	VWA8	psi-mi:“MI:0914”(association)	0.350
SAMTOR	MIF4GD	psi-mi:“MI:0914”(association)	0.350
C1QTNF2	GNPAT	psi-mi:“MI:0914”(association)	0.350
DEPDC5	SZT2	psi-mi:“MI:0914”(association)	0.350
RAP2A	CHEK1	psi-mi:“MI:0914”(association)	0.350
ADAM19	TSC22D2	psi-mi:“MI:0914”(association)	0.350
C1QTNF2	COL2A1	psi-mi:“MI:0914”(association)	0.350
DEPDC5	GLA	psi-mi:“MI:0914”(association)	0.350
OTUD3	MLF1	psi-mi:“MI:0914”(association)	0.350
CARHSP1	ITFG2	psi-mi:“MI:0914”(association)	0.350
KPTN	ALDH1A2	psi-mi:“MI:0914”(association)	0.350
OTUD3	MIB1	psi-mi:“MI:0914”(association)	0.350

BioGRID (58): ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), C12orf66 (Affinity Capture-MS), SZT2 (Affinity Capture-MS), SH3PXD2B (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5PJB7, A0A1L8HX76, A6QR40, O08764, O60294, O95382, P10938, P70218, P97452, Q12851, Q14137, Q15334, Q16586, Q28686, Q32P44, Q3TJ91, Q499N3, Q499U2, Q4KLI9, Q561R2, Q562C2, Q5RBH8, Q5RCX2, Q61161, Q6AY79, Q6F5E8, Q6P1M3, Q6V7V2, Q7SZE3, Q7TMC8, Q80Y17, Q8BYZ7, Q8C3I8, Q8C6B2, Q8CHW4, Q8K4K5, Q8MKF0, Q8N0W3, Q8VC03, Q91WI7

Diamond homologs: Q27969, Q5RBH8, Q91WI7, Q969R8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ITFG2	“form complex”	“KICSTOR complex”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

161 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	137
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3383984	NM_018463.4(ITFG2):c.848-1G>A	Likely pathogenic

SpliceAI

3392 predictions. Top by Δscore:

Variant	Effect	Δscore
12:2817215:A:AG	acceptor_gain	1.0000
12:2817215:ATTT:A	acceptor_gain	1.0000
12:2817216:T:G	acceptor_gain	1.0000
12:2817218:T:A	acceptor_gain	1.0000
12:2817218:TGAA:T	acceptor_loss	1.0000
12:2817220:AAGT:A	acceptor_loss	1.0000
12:2817221:A:AG	acceptor_gain	1.0000
12:2817221:A:AT	acceptor_loss	1.0000
12:2817222:G:GG	acceptor_gain	1.0000
12:2817222:GTT:G	acceptor_gain	1.0000
12:2817222:GTTA:G	acceptor_gain	1.0000
12:2817222:GTTAA:G	acceptor_gain	1.0000
12:2817803:G:GG	donor_gain	1.0000
12:2818155:T:TA	acceptor_gain	1.0000
12:2818307:GGAGA:G	donor_gain	1.0000
12:2818308:GAGAG:G	donor_gain	1.0000
12:2818309:A:T	donor_gain	1.0000
12:2818310:GA:G	donor_gain	1.0000
12:2818312:G:GG	donor_gain	1.0000
12:2818315:GGA:G	donor_gain	1.0000
12:2818316:GAG:G	donor_gain	1.0000
12:2818318:G:GG	donor_gain	1.0000
12:2820082:ACAG:A	acceptor_loss	1.0000
12:2820083:CAGA:C	acceptor_loss	1.0000
12:2820084:A:AG	acceptor_gain	1.0000
12:2820084:AGAT:A	acceptor_gain	1.0000
12:2820085:G:GT	acceptor_gain	1.0000
12:2820085:GATG:G	acceptor_gain	1.0000
12:2820222:TCAGG:T	donor_loss	1.0000
12:2820223:CAGGT:C	donor_loss	1.0000

AlphaMissense

2917 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:2821596:G:T	G283W	1.000
12:2821692:G:A	G283E	1.000
12:2821692:G:T	G283V	1.000
12:2822827:T:A	W328R	1.000
12:2822827:T:C	W328R	1.000
12:2820125:A:T	D149V	0.999
12:2820128:G:C	R150P	0.999
12:2820208:T:A	W177R	0.999
12:2820208:T:C	W177R	0.999
12:2821579:C:A	A277D	0.999
12:2821596:G:A	G283R	0.999
12:2821596:G:C	G283R	0.999
12:2822829:G:C	W328C	0.999
12:2822829:G:T	W328C	0.999
12:2822834:G:A	G330E	0.999
12:2822834:G:T	G330V	0.999
12:2822876:T:C	F344S	0.999
12:2817233:T:C	L36P	0.998
12:2820124:G:C	D149H	0.998
12:2821586:C:G	C279W	0.998
12:2821591:T:C	L281P	0.998
12:2821593:G:C	D282H	0.998
12:2821594:A:T	D282V	0.998
12:2821692:G:C	G283A	0.998
12:2821698:T:C	L285P	0.998
12:2821739:T:A	W299R	0.998
12:2821739:T:C	W299R	0.998
12:2822819:C:A	A325E	0.998
12:2822830:G:C	D329H	0.998
12:2822840:C:A	T332K	0.998

dbSNP variants (sampled 300 via entrez): RS1000043980 (12:2829941 G>A,T), RS1000069714 (12:2851019 T>A), RS1000135508 (12:2819006 C>T), RS1000262938 (12:2845717 A>T), RS1000318680 (12:2850913 T>C), RS1000330666 (12:2830958 C>A,G,T), RS1000641812 (12:2819953 G>A), RS1000642943 (12:2828802 A>G), RS1000701165 (12:2823277 C>T), RS1000708814 (12:2840866 G>A), RS1000730418 (12:2839693 G>A,T), RS1000739096 (12:2817530 G>A), RS1000746033 (12:2854224 C>T), RS1000748645 (12:2823521 G>C), RS1000755643 (12:2814241 G>C)

Disease associations

OMIM: gene MIM:617421 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal recessive

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, decreases expression	4
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
beta-N-methylamino-L-alanine	increases expression	1
chloroacetaldehyde	decreases expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases methylation	1
Resveratrol	affects cotreatment, increases expression	1
Zoledronic Acid	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Cidofovir	affects expression	1
Air Pollutants	affects expression, increases abundance	1
Ethanol	decreases expression, increases abundance, affects cotreatment	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Ifosfamide	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Oxygen	increases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice